Microba Life Sciences Limited
ASX:MAP Stok Raporu
Microba Life Sciences Temettüler ve Geri Alımlar
Temettü kriter kontrolleri 0/6 Microba Life Sciences şirketinin temettü ödeme geçmişi bulunmamaktadır.
Anahtar bilgiler Toplam Hissedar Getirisi -30.3% Gelecekteki Temettü Verimi 0% Temettü Büyümesi n/a Bir sonraki temettü ödeme tarihi n/a Eski temettü tarihi n/a Hisse başına temettü n/a Ödeme oranı n/a
Son temettü ve geri alım güncellemeleri
Tüm güncellemeleri göster
Microba Life Sciences Limited to Report Q1, 2025 Results on Oct 29, 2024 Oct 23
Microba Life Sciences Limited, Annual General Meeting, Nov 29, 2024 Oct 02
Microba Life Sciences Limited Announces Joint Company Secretary Changes Sep 05
Consensus EPS estimates upgraded to AU$0.035 loss Sep 04
Forecast to breakeven in 2027 Sep 02
Price target decreased by 11% to AU$0.34 Aug 30
Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 30
New major risk - Financial position Aug 13
Microba Life Sciences Limited to Report Q4, 2024 Results on Jul 25, 2024 Jul 23
Microba Life Sciences Limited to Report Q3, 2024 Results on Apr 23, 2024 Apr 19
New major risk - Revenue and earnings growth Feb 17
Microba Life Sciences Limited to Report Q2, 2024 Results on Jan 30, 2024 Jan 29 Microba Life Sciences Limited (ASX:MAP) completed the acquisition of Invivo Clinical Limited. Dec 06
New major risk - Shareholder dilution Nov 24
Consensus revenue estimates increase by 41% Nov 10
Price target decreased by 13% to AU$0.44 Nov 06
New minor risk - Share price stability Oct 23
Microba Life Sciences Limited, Annual General Meeting, Nov 30, 2023 Oct 12
Consensus estimates of losses per share improve by 26% Sep 05
Full year 2023 earnings: EPS and revenues exceed analyst expectations Aug 31
New minor risk - Financial data availability Aug 25
We're Hopeful That Microba Life Sciences (ASX:MAP) Will Use Its Cash Wisely Aug 01
Microba Life Sciences Limited to Report Q4, 2023 Results on Jul 27, 2023 Jul 25
Microba Life Sciences Limited Announces $2.92 Million Grant Award to QUT, in Collaboration with Microba to Develop a Human Microbiome Biobank Jun 27
Microba Life Sciences Limited Announces the Resignation of Caroline Popper as a Director, Effective June 14, 2023 Jun 06
Insider recently bought AU$126k worth of stock May 13
Price target decreased by 13% to AU$0.44 May 01
We're Not Very Worried About Microba Life Sciences' (ASX:MAP) Cash Burn Rate Apr 28
First half 2023 earnings released: AU$0.02 loss per share (vs AU$0.029 loss in 1H 2022) Feb 24
Microba Life Sciences Limited Completes its Immuno-Oncology Program Feb 02
Microba Life Sciences Limited to Report Q2, 2023 Results on Jan 30, 2023 Jan 30 Microba Life Sciences Limited has completed a Follow-on Equity Offering in the amount of AUD 17.833269 million. Dec 01
Stephen Fairy to Join Medical Advisory Board of Microba Life Sciences Limited Nov 30
Microba Life Sciences Limited to Report Q1, 2023 Results on Oct 27, 2022 Oct 27
Microba Life Sciences Limited, Annual General Meeting, Nov 25, 2022 Oct 07
Microba Life Sciences Limited Appoints Jacqueline Fernley as an Independent Non-Executive Director Sep 08
Microba Life Sciences Limited Provides Update on Therapeutic Programs Aug 31
Full year 2022 earnings: EPS exceeds analyst expectations Aug 29
Microba Life Sciences Limited Receives Two Ausindustry Advanced Overseas Findings Jul 22
Microba Life Sciences Limited to Report Fiscal Year 2022 Results on Jul 20, 2022 Jul 19
Is Microba Life Sciences (ASX:MAP) In A Good Position To Invest In Growth? Jul 05
Microba Life Sciences Limited Releases a Next Generation Product for Health Professionals Under a Closed Beta Access Program Jun 24
Microba Life Sciences Limited Announces Its Autoimmune Disease Program Has Officially Commenced Jun 09
Microba Accelerates Cancer Program with New Leads May 05
Microba Life Sciences Limited Appoints Trent Munro as Senior Vice President of Therapeutics Apr 06
First half 2022 earnings released Apr 05
Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: MAP şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.
Büyüyen Temettü: MAP şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.
Piyasaya Karşı Temettü Getirisi Microba Life Sciences Piyasaya Karşı Temettü Getirisi
MAP temettü verimi piyasa ile karşılaştırıldığında nasıldır? Segment Temettü Verimi Şirket (MAP) n/a Pazarın Alt %25'i (AU) 2.6% Pazarın En İyi %25'i (AU) 6.1% Sektör Ortalaması (Healthcare) 2.7% Analist tahmini (MAP) (3 yıla kadar) 0%
Önemli Temettü: MAP şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.
Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, MAP şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: MAP şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranı nı hesaplamak üzere yeterli veri yok.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: MAP herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.
Güçlü temettü ödeyen şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd Level 7, 320 Pitt Street, Sydney Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}